Articles about 'Babraham Institute'

Three companies, Astex Pharmaceuticals, Eisai Ltd and Eli Lilly and Company, are joining forces with research scientists across Cambridge to explore promising new approaches to the treatment of neurodegenerative disease.

Research led by the University of Cambridge has demonstrated the benefits and outputs from the significant taxpayer investment into the Babraham Research Campus; evidencing the overall economic, social and scientific contribution the Campus makes to the UK economy.  

Scientists at the University of Cambridge have for the first time shown that it is possible to derive from a human embryo so-called ‘naïve’ pluripotent stem cells – one of the most flexible types of stem cell, which can develop into all human tissue other than the placenta.

A rare DNA base, previously thought to be a temporary modification, has been shown to be stable in mammalian DNA, suggesting that it plays a key role in cellular function.